Exploratory kidney and blood-pressure signals warrant follow-up after unblinding.
The research question
Can routine-care biomarkers generate hypotheses while incretin trial assignments remain blinded?
Overview
The study explored organ-specific biomarker patterns across metabolic therapies.
Study design & methods
Twenty-five masked CagriSema/placebo participants were matched to 125 tirzepatide and 125 empagliflozin users; separate pramlintide comparisons provided pharmacologic context.
Principal findings
At six months, eGFR rose 26.4% in the masked cohort versus 6.5% with tirzepatide. Weight changes were not significantly different.
Limitations & interpretation
Preprint; not peer reviewed. The small, mixed active-treatment/placebo cohort cannot establish CagriSema efficacy or attribute signals to amylin. Residual confounding and routine-care measurement limit interpretation.
Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.